Download PDF
Semin Thromb Hemost 2021; 47(04): 400-418
DOI: 10.1055/s-0041-1727282
Review Article

Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis

Emmanuel J. Favaloro 
1   Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia
2   School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia
,
Brandon Michael Henry 
3   Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Ohio
,
Giuseppe Lippi 
4   Section of Clinical Biochemistry, University of Verona, Verona, Italy
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

von Willebrand factor (VWF) is a large adhesive multimeric protein involved in hemostasis. The larger the size (or number of VWF multimers), the greater the functionality of the protein. A deficiency or defect of VWF can lead to von Willebrand disease (VWD) and cause bleeding. Conversely, an increase in VWF may create an environment that promotes thrombosis. ADAMS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), sometimes called VWF-cleaving protease, is primarily responsible for controlling the size of VWF. The most severe deficiency (<10% of normal levels) of ADAMTS-13 arises in thrombotic thrombocytopenic purpura, a condition characterized by the presence of ultralarge VWF and clinically resulting in enhanced risk of thrombosis. However, ADAMTS-13 deficiency may result from other pathological processes. Of relevance is the recent finding that COVID-19 (coronavirus disease 2019) is associated with both increased levels and activity of VWF as well as generally decreased (or occasionally normal) activity levels of ADAMTS-13. Thus, in COVID-19 there is an alteration in the VWF/ADAMTS-13 axis, most often described by increased VWF/ADAMTS-13 ratio (or reduced ADAMTS-13/VWF ratio). COVID-19 is also associated with high prothrombotic risk. Thus, the imbalance of VWF and ADAMTS-13 in COVID-19 may be providing a milieu that promotes (micro)thrombosis, in a clinical picture resembling a secondary thrombotic microangiopathy in some patients. This review therefore assesses the literature on VWF, ADAMTS-13, and COVID-19. Whenever reported in COVID-19, VWF has always been identified as raised (compared with normal reference ranges or control populations). Reports have included VWF level (i.e., VWF antigen) and in some cases one or more VWF “activity” (e.g., collagen binding; platelet glycoprotein Ib [GPIb] binding, using ristocetin cofactor or more modern versions including VWF:GPIbR [recombinant] and VWF:GPIbM [mutant]). Whenever reported, ADAMTS-13 has been reported as “normal” or reduced; however, it should be recognized that “normal” levels may still identify a relative reduction in individual cases. Some reports also discuss the raised VWF/ADAMTS-13 (or reduced ADAMTS-13/VWF) ratio, but very few provide actual numerical data.

Keywords

von Willebrand factor - ADAMTS-13 - COVID-19 - thrombosis


Publication History

Article published online:
23 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014; 40 (01) 17-27
    PubMedSearch in Google Scholar
  • 2 Favaloro EJ, Pasalic L, Curnow J. Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 2017; 43 (03) 338-354
    PubMedSearch in Google Scholar
  • 3 Calabrò P, Gragnano F, Golia E, Grove EL. von Willebrand factor and venous thromboembolism: pathogenic link and therapeutic implications. Semin Thromb Hemost 2018; 44 (03) 249-260
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost 2020; 46 (03) 289-301
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019; 12 (03) 333-337
    CrossrefPubMedSearch in Google Scholar
  • 6 Favaloro EJ, Henry BH, Lippi G. VWF and ADAMTS13 in COVID-19 and beyond: a question of balance. 2021 ; in press
    PubMedSearch in Google Scholar
  • 7 Panigada M, Bottino N, Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18 (07) 1738-1742
    CrossrefPubMedSearch in Google Scholar
  • 8 Poissy J, Goutay J, Caplan M. et al; Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142 (02) 184-186
    CrossrefPubMedSearch in Google Scholar
  • 9 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
    CrossrefPubMedSearch in Google Scholar
  • 10 Goshua G, Pine AB, Meizlish ML. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7 (08) e575-e582
    CrossrefPubMedSearch in Google Scholar
  • 11 Ladikou EE, Sivaloganathan H, Milne KM. et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?. Clin Med (Lond) 2020; 20 (05) e178-e182
    CrossrefPubMedSearch in Google Scholar
  • 12 Masi P, Hékimian G, Lejeune M. et al. Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: insights from a prospective, single-center cohort study. Circulation 2020; 142 (06) 611-614
    CrossrefPubMedSearch in Google Scholar
  • 13 Sardu C, Marfella R, Maggi P. et al. Implications of ABO blood group in hypertensive patients with covid-19. BMC Cardiovasc Disord 2020; 20 (01) 373
    CrossrefPubMedSearch in Google Scholar
  • 14 Rauch A, Labreuche J, Lassalle F. et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J Thromb Haemost 2020; 18 (11) 2942-2953
    CrossrefPubMedSearch in Google Scholar
  • 15 Hoechter DJ, Becker-Pennrich A, Langrehr J. et al. Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients. Thromb Res 2020; 196: 186-192
    CrossrefPubMedSearch in Google Scholar
  • 16 Taus F, Salvagno G, Canè S. et al. platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler Thromb Vasc Biol 2020; 40 (12) 2975-2989
    CrossrefPubMedSearch in Google Scholar
  • 17 Fan BE, Ng J, Chan SSW. et al. COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. J Thromb Thrombolysis 2021; 51 (03) 663-674
    CrossrefPubMedSearch in Google Scholar
  • 18 Cugno M, Meroni PL, Gualtierotti R. et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun 2021; 116: 102560
    CrossrefPubMedSearch in Google Scholar
  • 19 Ward SE, Curley GF, Lavin M. et al; Irish COVID-19 Vasculopathy Study (ICVS) Investigators. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol 2021; 192 (04) 714-719
    CrossrefPubMedSearch in Google Scholar
  • 20 Ruberto F, Chistolini A, Curreli M. et al; Policlinico Umberto I COVID-19 Group. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. J Thromb Thrombolysis 2021; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 21 Heinz C, Miesbach W, Herrmann E. et al. Greater fibrinolysis resistance but no greater platelet aggregation in critically ill COVID-19 patients. Anesthesiology 2021; 134 (03) 457-467
    CrossrefPubMedSearch in Google Scholar
  • 22 Philippe A, Chocron R, Gendron N. et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 23 Vassiliou AG, Keskinidou C, Jahaj E. et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients. Cells 2021; 10 (01) 186
    CrossrefPubMedSearch in Google Scholar
  • 24 Bauer W, Galtung N, Neuwinger N. et al. A matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department. TH Open 2021; 5 (01) e43-e55
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Martinelli N, Montagnana M, Pizzolo F. et al. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res 2020; 193: 170-172
    CrossrefPubMedSearch in Google Scholar
  • 26 Rovas A, Osiaevi I, Buscher K. et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 2021; 24 (01) 145-157
    CrossrefPubMedSearch in Google Scholar
  • 27 Alharthy A, Faqihi F, Balhamar A, Memish ZA, Karakitsos D. Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: a case series. SAGE Open Med Case Rep 2020; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 28 Huisman A, Beun R, Sikma M, Westerink J, Kusadasi N. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol 2020; 42 (05) e211-e212
    CrossrefPubMedSearch in Google Scholar
  • 29 Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med 2020; 15 (05) 861-863
    CrossrefPubMedSearch in Google Scholar
  • 30 Morici N, Bottiroli M, Fumagalli R, Marini C, Cattaneo M. Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink. Thromb Haemost 2020; 120 (09) 1339-1342
    Thieme ConnectPubMedSearch in Google Scholar
  • 31 Blasi A, von Meijenfeldt FA, Adelmeijer J. et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost 2020; 18 (10) 2646-2653
    CrossrefPubMedSearch in Google Scholar
  • 32 Tiscia GL, Favuzzi G, De Laurenzo A. et al; CSS COVID-19 Group. Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients. TH Open 2020; 4 (03) e203-e206
    Thieme ConnectPubMedSearch in Google Scholar
  • 33 Fraser DD, Patterson EK, Slessarev M. et al. Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor 2020; 2 (09) e0194
    CrossrefPubMedSearch in Google Scholar
  • 34 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Evidence for secondary thrombotic microangiopathy in COVID-19. medRxiv 2020; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 35 Hardy M, Michaux I, Lessire S. et al. Prothrombotic hemostasis disturbances in patients with severe COVID-19: individual daily data. Data Brief 2020; 33: 106519
    CrossrefPubMedSearch in Google Scholar
  • 36 Mancini I, Baronciani L, Artoni A. et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 2021; 19 (02) 513-521
    CrossrefPubMedSearch in Google Scholar
  • 37 Henry BM, Benoit SW, de Oliveira MHS, Lippi G, Favaloro EJ, Benoit JL. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. Int J Lab Hematol 2020; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 38 Arulkumaran N, Thomas M, Brealey D. et al. Plasma exchange for COVID-19 thrombo-inflammatory disease. EJHaem 2020; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 39 Delrue M, Siguret V, Neuwirth M. et al. von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate-to-severe COVID-19 patients. Br J Haematol 2021; 192 (06) 1097-1100
    CrossrefPubMedSearch in Google Scholar
  • 40 Fernández-Pérez MP, Águila S, Reguilón-Gallego L. et al. Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID-19 outcomes. Clin Transl Med 2021; 11 (01) e268
    CrossrefPubMedSearch in Google Scholar
  • 41 Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D, Gil Alos D, Ayala R, Martinez-Lopez J. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Int J Lab Hematol 2021; (ePub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 42 De Jongh R, Ninivaggi M, Mesotten D. et al. Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis 2021; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 43 De Cristofaro R, Liuzzo G, Sacco M, Lancellotti S, Pedicino D, Andreotti F. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. Blood Coagul Fibrinolysis 2021; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 44 von Meijenfeldt FA, Havervall S, Adelmeijer J. et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haemost 2020; 5 (01) 132-141
    CrossrefPubMedSearch in Google Scholar
  • 45 Falter T, Rossmann H, Menge P. et al. No evidence for classic thrombotic microangiopathy in COVID-19. J Clin Med 2021; 10 (04) 671
    CrossrefPubMedSearch in Google Scholar
  • 46 Pascreau T, Zia-Chahabi S, Zuber B, Tcherakian C, Farfour E, Vasse M. ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19. Thromb Res 2021; (epub ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 47 Doevelaar AAN, Bachmann M, Hölzer B. et al. von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med 2021; 49 (05) e512-e520
    CrossrefPubMedSearch in Google Scholar
  • 48 Favaloro EJ. Navigating the myriad of von Willebrand factor assays. Hamostaseologie 2020; 40 (04) 431-442
    Thieme ConnectPubMedSearch in Google Scholar
  • 49 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2016; 141: 202-211
    CrossrefPubMedSearch in Google Scholar
  • 50 Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104 (05) 1009-1021
    Thieme ConnectPubMedSearch in Google Scholar
  • 51 Oliver S, Vanniasinkam T, Mohammed S, Vong R, Favaloro EJ. Semi-automated von Willebrand factor multimer assay for von Willebrand disease: further validation, benefits and limitations. Int J Lab Hematol 2019; 41 (06) 762-771
    CrossrefPubMedSearch in Google Scholar
  • 52 Favaloro EJ. Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies. Res Pract Thromb Haemost 2020; 4 (06) 952-957
    CrossrefPubMedSearch in Google Scholar
  • 53 Favaloro EJ, Oliver S, Mohammed S, Vong R. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies. Haemophilia 2020; 26 (03) 503-512
    CrossrefPubMedSearch in Google Scholar
  • 54 Favaloro EJ, Mohammed S, Chapman K. et al. A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. J Thromb Haemost 2021; 19 (02) 417-428
    CrossrefPubMedSearch in Google Scholar
  • 55 Favaloro EJ, Thachil J. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. Clin Chem Lab Med 2020; 58 (08) 1191-1199
    CrossrefPubMedSearch in Google Scholar
  • 56 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
    CrossrefPubMedSearch in Google Scholar
  • 57 Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost 2020; 46 (07) 781-784
    Thieme ConnectPubMedSearch in Google Scholar
  • 58 Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: Is it pulmonary thrombosis or pulmonary embolism?. Semin Thromb Hemost 2020; 46 (07) 777-780
    Thieme ConnectPubMedSearch in Google Scholar
  • 59 Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020; 46 (07) 772-776
    Thieme ConnectPubMedSearch in Google Scholar
  • 60 Annane D, Heming N, Grimaldi-Bensouda L. et al; Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 2020; 28: 100590
    CrossrefPubMedSearch in Google Scholar
  • 61 Laurence J, Mulvey JJ, Seshadri M. et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol 2020; 219: 108555
    CrossrefPubMedSearch in Google Scholar
  • 62 Giudice V, Pagliano P, Vatrella A. et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol 2020; 11: 857
    CrossrefPubMedSearch in Google Scholar